Full-Time
Senior Software Engineer
Posted on 11/14/2025
Myriad Genetics
1,001-5,000 employees
Genetic testing and molecular diagnostics
No salary listed
Remote in USA
Remote
 Software Engineering (1) |
|---|
- Computer science background.
- 8+ years of industry experience building backend applications.
- Experience with Python and Django
- Experience with SQL and PostgreSQL.
- Familiarity in building and deploying with cloud native technologies such as AWS (EKS and Serverless).
- Demonstrated skill in API design both REST and GraphQL.
- Familiarity/experience with event-driven architecture patterns using Kafka, Kinesis, RabbitMQ.
- Demonstrated experience with Xifin, medical billing and/or financial systems.
- Applicant must be a U.S. citizen or national, U.S. lawful permanent resident (aka green card holder)
- Implement, and maintain the core architecture of our services.
- Perform development, code review, testing, and deployment to ship quality code to production.
- Develop new Python services from the ground up and maintain and modernize existing services.
- Work with managers and stakeholders to build creative solutions using an agile process.
- Level up other engineers, the team, and the rest of the organization with technical skills, open communication, and subject matter expertise.
- Use modern software tools including Python, Django, OpenAPI, AWS, and Docker.
- Be a clear role model for engineering quality. Introduces and promotes new tooling and practices for the team.
- Provide data-driven impact and risk analysis with any system changes.
- Provide professional presentation and knowledge sharing.
Myriad Genetics develops molecular diagnostic solutions by offering genetic tests that identify inherited and disease-associated variants for cancer, autoimmune diseases, and other conditions. Its offerings help patients and healthcare professionals with risk assessment, early detection, and personalized treatment planning based on an individual’s genetic profile. The tests are performed on patient samples (such as blood or tissue) and generate reports with clinically actionable results that guide decisions about prevention, surveillance, and therapy. The company differentiates itself through its focus on accuracy, secure handling of personal genetic information, and clear, actionable results derived from established genetic panels and tests. Myriad’s goal is to improve and save lives by making precise genetic insights accessible to patients and clinicians, enabling better patient care and outcomes.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Salt Lake City, Utah
Founded
1991
Simplify's Take
What believers are saying
- Cancer Care Continuum volumes grew 13% YoY in Q1 2026, driving hereditary cancer expansion.
- Prolaris AI launch June 2026 and accelerated Precise MRD rollout to colorectal, renal cancers.
- SOPHiA GENETICS collaboration expands pharma services and liquid biopsy companion diagnostic opportunities.
What critics are saying
- Prenatal revenue declined 15% YoY in Q1 2026 from Natera and Illumina competition.
- Invitae's low-cost hereditary cancer panels undercut MyRisk pricing, eroding market share.
- Negative adjusted EBITDA of $4.5M in Q1 2026 threatens $125M term loan covenants.
What makes Myriad Genetics unique
- FDA-approved MyChoice CDx companion diagnostic for GSK's Zejula ovarian cancer drug.
- Integrated AI-genetic risk platform with Clairity and MagView for personalized breast health.
- Precise MRD liquid biopsy detects circulating tumor DNA at one part per million.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Company News
Myriad Genetics has received FDA approval for its MyChoice CDx Test as the companion diagnostic for Zejula (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer. The approval is based on final data from the PRIMA trial. MyChoice CDx is now the only FDA-approved companion diagnostic test in the United States to identify patients with homologous recombination deficiency-positive status eligible for Zejula treatment. The test uses next-generation sequencing technology to assess BRCA1/2 genes and tumour genomic instability score. Nearly 50% of patients with advanced ovarian cancer have HRD-positive tumours. The test can identify 34% more patients with HRD than other tumour tests using loss of heterozygosity alone. Zejula is approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Shares of Myriad Genetics rose 4.9% to $5.26 after the company announced the launch of its Precise MRD test for breast cancer patients and presented at the TD Cowen 46th Annual Health Care Conference. The new test detects molecular residual disease to help doctors monitor patients during cancer treatment. Myriad Genetics initiated the launch with select oncology practices, with plans for broader US rollout later this year. The company recently reaffirmed its full-year 2026 financial outlook. Myriad Genetics has experienced significant volatility, with 45 moves greater than 5% over the past year. The stock is down 14.4% year-to-date and trading 50% below its 52-week high of $10.52 from March 2025.
Myriad Genetics has commercially launched its Precise MRD test with select community oncology practices for breast cancer patients. The tumor-informed circulating tumour DNA assay uses whole-genome sequencing to create personalised panels and can detect ctDNA at levels as low as one part per million. The initial rollout involves selected oncology practices with no patient limit, whilst a broader US launch is planned for later this year. The test enables longitudinal monitoring during cancer treatment, helping clinicians determine if adjuvant treatment is needed, whether cancer has recurred, or if treatment is working. Precise MRD provides molecular insights across the cancer care continuum, with results displayed in reports showing ctDNA detection and concentration over time. The company positions the test as enabling earlier insight and more informed treatment decisions.
Myriad Genetics launching breast cancer MRD in March, posts flat Q4 revenue. NEW YORK - Myriad Genetics said Monday that it will begin sales of its Precise molecular residual disease (MRD) test at the beginning of March. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month
Clairity, Myriad Genetics, and MagView launch the first integrated AI and genetic risk platform for personalized breast health. Actionable offering helps enable earlier, more personalized breast cancer interventions. BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) - Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leaders in breast cancer: * Clairity - developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman's five-year breast cancer risk directly from a routine mammogram * Myriad Genetics - a leader in molecular diagnostic testing and precision medicine, offering the MyRisk(R) Hereditary Cancer Test with RiskScore(R), which combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk * MagView - a leader in comprehensive software solutions for breast imaging centers For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad's MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView's Luminary Risk platform, which supports breast cancer risk assessment programs across the United States. "By integrating directly with MagView alongside Myriad, we are giving clinicians a more complete and actionable view of risk than can be achieved using age and family history alone," said Jeff Luber, CEO, Clairity, "Using AI-powered risk assessment, Clairity Breast identifies women at the highest risk from a routine mammogram." "Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum," said Sam Raha, President and CEO, Myriad Genetics. "By pairing the MyRisk Hereditary Cancer Test with Clairity's AI-powered risk assessment within MagView's workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer." "Our platform streamlines how risk information is captured, interpreted, and acted on," said Bryan Chapin, President and CEO, MagView. "Integrating Clairity and MyRisk into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency." About Clairity Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first and only FDA-authorized offering to estimate a woman's five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act earlier, save lives, and lower the overall cost of cancer care. To learn more about indications for use, visit: https://clairity.com/clairity-breast/. About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. About MagView MagView is the leader in breast imaging workflow solutions for mammography reporting, tracking, workflow, compliance, and high-risk screening. Headquartered in Fulton, Maryland, MagView's Luminary Risk software embeds into EHRs to enable breast centers to adopt a more personalized approach to breast cancer screening, focusing on patient experience and staff efficiency. MagView is utilized by more than 2,500 facilities across the U.S., including many of the nation's top cancer centers. For more information about MagView, please visit www.magview.com. Myriad Genetics Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to how the joint collaboration aims to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens; expectations that integrating Clarity into MagView alongside Myriad gives clinicians a more complete and actionable view of risk than can be achieved using age and family history alone; by pairing the MyRisk Hereditary Cancer Test with Clairity's AI-powered risk assessment within MagView's workflow, Myriad aims to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer; and statements regarding the potential for the integration of Clairity Breast and MyRisk into one platform to give providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.